Medacta Group SA (MEDGF) Stock Price & Analysis
MEDGF Stock Chart & Stats
- Day’s Range
- $135.90 - $149.73
- 52-Week Range
- $126.02 - $234.65
- Previous Close
- $146.60
- Volume
- 75
- Average Volume (3M)
- 0
- Market Cap
- $2.85B
- Enterprise Value
- $2.98B
- Total Cash (Recent Filing)
- $36.10M
- Total Debt (Recent Filing)
- $321.58M
- Price to Earnings (P/E)
- 32.8
- Beta
- 0.69
- Next Earnings
- Mar 12, 2027 (Est.)
- EPS Estimate
- 3.08
- Last Dividend Ex-Date
- May 08, 2026
- Dividend Yield
- 2.09%
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth
The strong multi-year revenue expansion indicates continuing demand for Medacta's orthopedic and spine solutions. Broad growth across regions and product categories supports scale, reinforces surgeon and hospital adoption, and provides a durable base for further operating leverage.
Product And Geographic Expansion
Regulatory approval in India expands Medacta's addressable market and creates a new channel for implant growth beyond established regions. Combined with new products and planned U.S. expansion, this supports longer-term geographic diversification and future procedure adoption.
Improving Balance Sheet
The substantial increase in equity and lower debt-to-equity ratio indicate a stronger capital base and improved balance-sheet resilience. This gives Medacta greater flexibility to fund capacity, research, and market expansion while retaining more ability to absorb operating volatility.
Bears Say
Margin Compression
The sustained decline in gross margin raises questions about how much of Medacta's historical profitability can be preserved as product and geographic mix evolve. Price erosion, foreign exchange, and lower-margin growth can limit earnings conversion even when revenue remains strong.
Uneven Free Cash Flow
Free-cash-flow conversion remains modest and inconsistent relative to reported earnings, reflecting reinvestment and working-capital swings. This can constrain internally funded expansion and make cash availability more sensitive to inventory requirements and the timing of growth investments.
U.S. Customer Attrition
Existing-customer attrition in the U.S. threatens the recurring procedure volume that supports implant utilization and surgeon relationships. Although new products and customers may offset the issue, continued switching or care migration could slow Medacta's growth in a strategically important market.
Medacta Group SA News
Medacta’s MPACT DM Cup Study: A Potential Game-Changer in Hip Arthroplasty
Medacta Group Sa (($MEDGF)) announced an update on their ongoing clinical study. Medacta Group SA is conducting a study titled ‘Prospective, Multicenter, Non-Controlled, Non-Randomized, Open-Label Study To Evaluate The Efficacy
Medacta’s GMK SpheriKA Study: A Potential Game-Changer in Knee Prosthesis
Medacta Group Sa (($MEDGF)) announced an update on their ongoing clinical study. The Medacta GMK SpheriKA Post-Marketing Surveillance Study, officially titled ‘Medacta GMK® SpheriKA and Kinematic Alignment Technique Multicenter, Post-Market
MEDGF FAQ
What was Medacta Group SA’s price range in the past 12 months?
What is Medacta Group SA’s market cap?
When is Medacta Group SA’s upcoming earnings report date?
How were Medacta Group SA’s earnings last quarter?
Is Medacta Group SA overvalued?
Does Medacta Group SA pay dividends?
What is Medacta Group SA’s EPS estimate?
How many shares outstanding does Medacta Group SA have?
What happened to Medacta Group SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medacta Group SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Medacta Group SA
Medacta Group S.A. is a worldwide enterprise specializing in the design, production, and distribution of medical devices for both orthopedic and neurosurgical applications. Operating across Europe, North America, the Asia-Pacific region, and numerous other international markets, the company delivers specialized solutions. These include custom kinematic models and three-dimensional planning software, which are employed in various surgical procedures such as those for the hip, knee, and shoulder, as well as in sports medicine and spinal treatments. The firm, established in 1958, maintains its primary corporate office in Castel San Pietro, Switzerland.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Francesco Siccardi
- Employees
- 2,273
- Website
- www.medacta.com
- Address
- Strada Regina, 34, Castel San Pietro, TI, 6874, CH
Medacta Group SA (MEDGF) Earnings & Revenues
MEDGF Company Deck
MEDGF Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, supported by almost 10% constant-currency revenue growth, above-market performance across most product categories and regions, confirmed 2026 and midterm guidance, product launches, India approval, and planned U.S. expansion. However, the period also included meaningful margin pressure, lower operating cash flow, negative free cash flow, a slower-than-expected U.S. market, customer attrition, Spanish strikes, and subdued spine growth. Highlights significantly outweighed the lowlights, although management acknowledged that reaching the midpoint of full-year guidance would be difficult.
View all MEDGF earnings summariesMEDGF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 2 | 0 | 10 |